Citigroup Inc. bought a new position in shares of Gritstone Oncology Inc (NASDAQ:GRTS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,823 shares of the company’s stock, valued at approximately $28,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Strs Ohio bought a new position in shares of Gritstone Oncology in the fourth quarter worth approximately $29,000. Riverhead Capital Management LLC bought a new position in Gritstone Oncology during the third quarter valued at approximately $141,000. Point72 Asset Management L.P. purchased a new stake in shares of Gritstone Oncology during the third quarter valued at approximately $142,000. Alliancebernstein L.P. purchased a new stake in shares of Gritstone Oncology during the third quarter valued at approximately $285,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Gritstone Oncology during the third quarter valued at approximately $385,000. Hedge funds and other institutional investors own 58.96% of the company’s stock.
Shares of GRTS stock remained flat at $$10.75 during trading hours on Friday. The stock had a trading volume of 767,139 shares, compared to its average volume of 182,419. Gritstone Oncology Inc has a 12-month low of $9.66 and a 12-month high of $32.90. The stock has a market cap of $313.96 million and a PE ratio of -1.48.
A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Gritstone Oncology in a research note on Monday, April 1st. Berenberg Bank began coverage on Gritstone Oncology in a research report on Wednesday, March 27th. They set a “buy” rating for the company. Finally, Raymond James began coverage on Gritstone Oncology in a report on Thursday, March 14th. They set an “outperform” rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Gritstone Oncology currently has a consensus rating of “Buy” and a consensus target price of $22.20.
TRADEMARK VIOLATION NOTICE: “Citigroup Inc. Buys Shares of 1,823 Gritstone Oncology Inc (GRTS)” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/citigroup-inc-acquires-new-holdings-in-gritstone-oncology-inc-grts.html.
Gritstone Oncology Profile
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
See Also: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.